Bayer is highlighting the approval of its Ultravist injection for contrast-enhanced mammography (CEM) by the U.S. Food and Drug Administration (FDA).
The company said this contrast agent, available in both 300 and 370 options, helps visualize known or suspected breast lesions in adults as an adjunct to mammography or ultrasound.
Bayer also said that this approval adds to the company's portfolio for breast imaging products and noted how CEM can allow for better visualization of abnormalities in breast tissue that may not be visible with standard mammography.
The FDA in 2022 approved the Ultravist injection to be imported to the U.S..
